Jinhuo Pharmaceutical Group (01110) announced its annual results for the year ended December 31, 2023. The group period...
According to Zhitong Finance App, Jinhuo Pharmaceutical Group (01110) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 1,079 billion yuan (RMB, same below) during the period, a year-on-year decrease of 12.63%; profit attributable to shareholders of RMB 38.96 million, an increase of 67.52% over the previous year; basic profit of 6.44 points per share; and plans to pay a final dividend of HK3.38 cents per share.
According to the announcement, the main reason for the increase in earnings was the increase in revenue from Kyoto Nenji-an Honey Refined Kawakai Loquat Cream. The main reason for this increase is due to the increase in market demand during the year under review compared to the recovery trend for the year ended 31 December 2022 due to the prevention and control of the epidemic and a better understanding of the epidemic. However, some of the medical equipment products manufactured for Dongdixin, including infrared thermometers, were offset by a decrease in sales. This type of epidemic prevention product is in high demand for the year ended 31 December 2022.